{"id":22925,"date":"2022-11-29T12:31:19","date_gmt":"2022-11-29T11:31:19","guid":{"rendered":"https:\/\/porib.com\/?p=22925"},"modified":"2022-11-29T12:31:19","modified_gmt":"2022-11-29T11:31:19","slug":"porib-presente-en-la-25-edicion-de-ispor","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/porib-presente-en-la-25-edicion-de-ispor\/","title":{"rendered":"PORIB presente en la 25 edici\u00f3n de ISPOR"},"content":{"rendered":"<div class=\"col80p\">\n<p>PORIB ha estado presente en ISPOR con la Comunicaci\u00f3n <em><strong>Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain<\/strong><\/em> de los autores C\u00f3rdoba R, L\u00f3pez-Corral L, Presa M, Mart\u00edn-Escudero V, Casado M\u00c1, Pardo C. Esta 25 edici\u00f3n se ha celebrado de nuevo de manera presencial en Viena del 6 al 9 de noviembre.<br \/>\nDe acuerdo con las conclusiones de la Comunicaci\u00f3n, se recomienda hacer esfuerzos por aumentar el n\u00famero de pacientes tratados con axicabtag\u00e9n ciloleucel (Yescarta\u00ae) en Espa\u00f1a debido a la mejor\u00eda significativa que ha demostrado en los resultados de salud en comparaci\u00f3n con quimioterapia, en pacientes con linfoma B difuso de c\u00e9lulas grandes en reca\u00edda o refractario tras dos o m\u00e1s l\u00edneas de tratamiento previo.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PORIB ha estado presente en ISPOR con la Comunicaci\u00f3n Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain de los autores C\u00f3rdoba R, L\u00f3pez-Corral L, Presa M, Mart\u00edn-Escudero V, Casado M\u00c1, Pardo C. Esta 25 edici\u00f3n se ha celebrado de nuevo&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/porib-presente-en-la-25-edicion-de-ispor\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":22926,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-22925","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/22925"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=22925"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/22925\/revisions"}],"predecessor-version":[{"id":22927,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/22925\/revisions\/22927"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/22926"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=22925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=22925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=22925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}